Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Neutral

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

By The Northwire Desk — AI Analysis Jun 24, 2026 · 08:00 ZCT · 0.14 Zero Candida Technologies Inc.
ZCT · Price

Executive Summary

  • Zero Candida Technologies, Inc. officially announced the grant of Patent No. 12654025B2, marking a significant milestone in its development of next-generation FemTech medical devices.
  • The patent covers the ZC-001, a smart, AI-enabled therapeutic device designed for the at-home treatment of Vulvovaginal Candidiasis (VVC) using precision blue light therapy, targeted drug delivery, and wireless diagnostics.
  • The technology is positioned to integrate advanced AI capabilities for disease detection, direct physician reporting, and automated pharmacy ordering, targeting a VVC treatment market projected to exceed US $2B by 2030.

Key Details

  • Patent Number: 12654025B2
  • Device Name: ZC-001
  • Core Technology: Integrates precision blue light therapy, targeted drug delivery, and wireless diagnostics for personalized at-home care.
  • Target Indication: Vulvovaginal Candidiasis (VVC), with a specific focus on recurrent (four or more episodes per year) and drug-resistant infections.
  • AI & Connectivity Features: Designed to evolve with AI capabilities to treat fungal infections, detect new diseases, report diagnostic data directly to physicians, and automatically order medication from pharmacies.
  • Clinical & Operational Rationale: Aims to improve patient outcomes, reduce the need for repeated in-clinic visits, and address a condition affecting approximately 75% of women globally.
  • Market Projection: The VVC treatment market is projected to exceed US $2 billion by 2030.
  • Company Tickers: TSXV: ZCT, OTCQB: ZCTFF, FSE: 9L2
Read the original news release →

More from Zero Candida Technologies Inc.

Feb 17, 2026 · 08:00

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Production / Operations Oct 20, 2025 · 09:00

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Production / Operations